SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-223659
Filing Date
2021-07-26
Accepted
2021-07-26 07:36:56
Documents
13
Period of Report
2021-07-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d217083d8k.htm   iXBRL 8-K 24886
2 EX-99.1 d217083dex991.htm EX-99.1 2981
  Complete submission text file 0001193125-21-223659.txt   147523

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20210723.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20210723_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20210723_pre.xml EX-101.PRE 10950
6 EXTRACTED XBRL INSTANCE DOCUMENT d217083d8k_htm.xml XML 3208
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 211112381
SIC: 2834 Pharmaceutical Preparations